The FDRR submission and OND meeting in Q4 2026 are the next binary catalysts. The outcome is uncertain but the decision timeline is uncertain; one of two recent ophthalmology FDRRs in 2026 was granted. The cash extension into 2029 removes near-term financing risk. Monitor for OND meeting scheduling and the FDRR decision, which could be a major catalyst for reproxalap's approval path.
Price Chart
Executive Summary
Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs, appealing the March 16, 2026 Complete Response Letter that denied approval of reproxalap for dry eye disease. The company also extended its projected operational cash runway into 2029, based on $45.1M in cash and cash equivalents as of June 30, 2026.
Key Facts
- Aldeyra intends to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs (OND) in Q4 2026, appealing the March 16, 2026 Complete Response Letter for reproxalap for dry eye disease.
- The FDRR is based on recent Type A and Type D meetings with the FDA; a meeting with OND is expected in Q4 2026.
- Cash and cash equivalents were $45.1M as of June 30, 2026; projected operational cash runway extended into 2029.
- Over three NDA submissions, Aldeyra provided data from nine adequate and well-controlled clinical trials, five of which achieved all multiplicity-controlled primary endpoints.
- Two FDRRs in 2026 for ophthalmological drug products in 2026: one resulted in an Appeal Granted decision; one is awaiting an advisory panel.
Financial Impact
Cash runway extended into 2029 on $45.1M cash; no revenue or EPS data provided.
Risk Factors
- FDRR outcome is uncertain; the FDA may request additional information, expert consultation, or an advisory panel, which could delay or deny the appeal.
- Reproxalap has received three Complete Response Letters; the FDA's position that the totality of evidence does not support effectiveness is a significant regulatory hurdle.
- No revenue-generating products; reliance on reproxalap approval for dry eye disease is critical to the company's value.
- Cash runway extension into 2029 assumes no material changes in spending; any additional clinical trials could change this.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-405954 |
| Document: aldx-ex99_2.htm | 0001193125-26-405954 |
| Document: aldx-ex99_1.htm | 0001193125-26-405954 |
| Document: 0001193125-26-405954-index-headers.html | 0001193125-26-405954 |
| Document: 0001193125-26-405954-index.html | 0001193125-26-405954 |
| Document: 0001193125-26-405954.txt | 0001193125-26-405954 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 28d ago | 8-K | $1.32 $0.6412 | ▼ −51.42% | ▼ −52.14% | $0.6412 (−51.42%) |
Aug 16, 2026 10w ago | Institutional Cluster | $1.56 $1.37 | ▲ +12.18% | ▲ +10.20% | $0.6412 (+58.90%) |
Jul 30, 2026 12w ago | 8-K | $1.54 $1.49 | ▼ −3.57% | ▼ −6.56% | $0.6412 (−58.36%) |
Apr 27, 2026 26w ago | DEFA14A | $1.57 $1.78 | ▲ +13.38% | ▲ +7.91% | $0.6412 (−59.16%) |
Apr 20, 2026 27w ago | 8-K | $1.68 $1.60 | ▼ −4.76% | ▼ −9.68% | $0.6412 (−61.83%) |
Mar 18, 2026 31w ago | Insider Cluster | $1.42 $1.80 | ▲ +26.76% | ▲ +20.71% | $0.6412 (−54.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers